Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
July 07 2022 - 04:30PM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that Noreen Roth Henig, M.D., Chief Medical Officer, will
participate in a panel called “Developing Therapies Against Novel
Targets in Autoimmune Diseases” at the William Blair Biotech Focus
Conference in New York, NY. The panel will be held in person on
Wednesday, July 13, 2022, at 11:00 am ET.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing breakthrough treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor being
evaluated in a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit
www.kezarlifesciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220707005143/en/
Investor Gitanjali Jain Vice President, Investor
Relations and External Affairs 650-269-7523 gjain@kezarbio.com
Media Liza Sullivan Argot Partners 212-600-1902
kezar@argotpartners.com
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kezar Life Sciences (NASDAQ:KZR)
Historical Stock Chart
From Mar 2023 to Mar 2024